Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alb-Flt3L fusion protein
- Development stage
- Discontinued
- Lead developer
- PapiVax Biotech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intramuscular (as Dna Via Electroporation), Subcutaneous
01
Overview
Alb-Flt3L fusion protein is a recombinant fusion protein consisting of Fms-like tyrosine kinase 3 ligand (Flt3L) fused to albumin. This design extends the serum half-life and bioactivity of Flt3L compared to the native cytokine. Flt3L is a key growth factor for dendritic cell (DC) development and expansion, particularly conventional DCs (cDCs) and plasmacytoid DCs (pDCs). The albumin-fusion strategy enhances tissue targeting and persistence in vivo, leading to more robust expansion of DC populations and improved anti-tumor immune responses in preclinical models. The drug is being developed primarily as an immunotherapy for cancer by Papivax Biotech[1][6][9].
- Other names
- albumin-fused Flt3Lalbumin-FMS-like tyrosine kinase 3 ligand fusion protein
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)FLT3LG (FLT3 ligand)
Beyond the preview
Go deeper on Alb-Flt3L fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alb-Flt3L fusion protein.